Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor–Containing cART Regimens in Antiretroviral-Naïve Patients Starting cART After January 1, 2000

REFERENCES

• Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://AIDSinfo.nih.gov. Accessed October 10,2006.
   Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Enql J Med. 2002;346:2039–2046.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Moralis-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Robbins GK, de Gruttola V, Shafer RW, et al. Comparison of sequential three drug regimens as initial therapy for HIV-1 infection. N Enql J Med. 2003;349:2293–2303.
   PubMed Web of Science ®Google Scholar
• INITIO Trial International Coordinating Committee. Viro-logical and immunological outcomes at 3 years after start-ing antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open label randomised trial. Lancet. 2006;368: 287–298.
   PubMed Web of Science ®Google Scholar
• Van Leeuwen R, Katlama C, Murphy PL, et al. A randomised trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected pa-tients. AIDS. 2003;17:987–999.
   PubMed Web of Science ®Google Scholar
• Van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2 NN study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. A randomised clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV infected naive patients (the Combine Study). Antiviral Ther. 2002;7:81–90.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 200115: 1679–1686.
   Google Scholar
• Bucher HC, Bichsel M, Taffe P, et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in pro-tease inhibitor-naïve HIV-infected patients: The Swiss HIV Cohort Study. HIV Med. 2002;3:247–253.
   PubMedGoogle Scholar
• Lundgren JD, Mocroft A, Gate JM, et al. A clinically prog-nostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002;185: 178–187.
   PubMed Web of Science ®Google Scholar
• Yerly S, Perneger TV, Hirschel B, et al. A critical assess-ment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med. 1998;158:247–252.
   PubMed Web of Science ®Google Scholar
• Cozzi Lepri A, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lym-phocyte counts in advanced HIV infection. AIDS. 1998;12:1639–1643.
   PubMed Web of Science ®Google Scholar
• Carpenter CCJ, Fisch! MA, Hammer SN, et al. Antiretroviral therapy for HIV in 1996: recommendations of an interna-tional panel. JAMA. 1996;276:146–154.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Rockstroh J, Soriano V, et al. Are specific antiretrovirals associated with an increased risk of discon-tinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antiviral Ther. 2005;10:779–790.
   Google Scholar
• Mocroft A, Phillips AN, Soriano V, et al. Reasons for stop-ping antiretrovirals used in an initial highly active antiretroviral regimen: results from the EuroSIDA study. AIDS Res Human Retro virus. 2005;21:743–752.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Johnson J, Herrera G, et al. Abacavir/ lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): E554001 (CLASS) preliminary 48 week results. In: Program and abstracts of the XIV International AIDS Conference; 2002; Barcelona, Spain. Abstract TuOrB1189.
   Google Scholar
• Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Enql J Med. 2003;349:2304–2315.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Grabar S, Tassie JM, et al. Use of observa-tional databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of co-hort studies with randomised trials. AIDS. 1999;13:2075–2082.
   PubMed Web of Science ®Google Scholar
• Kempf DJ, King MS, Bernstein B, et al. Incidence of resis-tance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51–60.
   PubMed Web of Science ®Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48 week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1 infected patients. J Acquir Immune Defic Syndr. 2004;35: 22–32.
   PubMed Web of Science ®Google Scholar
• Roge BT, Katzenstein TL, Nielsen HL, Gerstoft J. Drug resistance mutations and outcome of second-line treat-ment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Med. 2003;4:38–47.
   PubMedGoogle Scholar
• Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15: 1679–1686.
   PubMed Web of Science ®Google Scholar
• Fried! AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor and efavirenz containing antiretroviral combination therapy: The Swiss HIV Cohort study. AIDS. 200115: 1793–1800.
   Google Scholar
• Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS. 2002;16:53–61.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Bicshel M, Taffe P, et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in pro-tease-inhibitor naïve HIV infected patients: The Swiss HIV Cohort Study. HIV Med. 2002;3:247–253.
   PubMedGoogle Scholar
• Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic and clinical response to five different initial protease-inhibitor containing and nevirapine containing regimens. J Acquire Immune Defic Syndr. 2001;27:350–364.
   PubMed Web of Science ®Google Scholar
• Lampe FC, Gate!! JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy. Arch Intern Med. 2006;166:521–528.
   PubMed Web of Science ®Google Scholar
• Bannister WP, Kirk O, Gate J, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. JAIDS. 2006;42: 229–237.
   Google Scholar
• Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transciptase inhibitor containing and protease-in-hibitor containing regimens using observational data-bases. AIDS. 200115: 1133–1142.
   Google Scholar
• Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect com-parison of controlled trials. BMJ. 2004;328:249.
   PubMed Web of Science ®Google Scholar
• van Roon EN, VerzijI JM, Juttmann JR, Lenderinck AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral therapy (HAART) and its determi-nants. JAIDS. 1999;20:290–294.
   Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modifica-tion and discontinuation of antiretrovirals: results from a single treatment centre. AIDS. 2001;15:185–194.
   PubMed Web of Science ®Google Scholar
• d'Arminio Monfore A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS. 2000;14: 499–507.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. AIDS. 2006;20:1141–1150.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang W, Bakhai A. Comparison of Bayesian model averaging and stepwise methods for model selec-tion in logistic regression. Stats Med. 2004;23:3451–3467.
   Google Scholar